Secondaries' barrier is talent, not money

Golub Capital committed $1 billion to secondaries before it had a team to run the strategy, then hired Matt Shafer away from Northleaf Capital Partners on September 16, a sequence that, as PWD's tracking shows, inverts the usual order of fund building: capital first, people second.

The commitment was not contingent on Shafer's arrival or any other named professional; Golub had already put the money down before the hire. What that sequencing shows is the phone that rings when a secondaries trade needs to clear—the relationship map, the underwriting judgment, the ability to move from a GP's first call to a signed purchase agreement without a bank's balance sheet doing the work.

The same proposition shows up, inverted, in Gordian Investment Group's launch, where a former Children's Health allocator has left to build a secondaries firm on the premise that execution, not capital, is the binding constraint—a bet that the messy, structured, GP-led deals other buyers walk away from can be won by a team that knows how to underwrite them, rather than by the largest check. Golub bought access with capital before it had the team; Gordian is selling access as the product while raising less of the same commodity. Both moves testify that the secondaries market's new barrier to entry is sourcing and underwriting talent rather than money, and that the old barrier—fundraising momentum—has given way to the quality of the people who answer when a seller calls.

In any normal fund business, capital follows the team, track record, and strategy; Golub reversed that order by announcing $1 billion before it had anyone to deploy it, which only makes sense if it judged secondaries talent so scarce that it could not wait for the people before reserving the capital. The capital was the easy part; the people were the hard part, and the capital was a down payment on the people.

Matt Shafer's arrival from Northleaf is the people part, and in this market it is closer to an acquisition of an origination network. Northleaf has been a participant in secondaries and direct investments, so a senior professional leaving that platform for a newcomer with a $1 billion head start suggests the $1 billion was the recruiting pitch.

Gordian's launch is a different wager: if capital is plentiful and talent is scarce, then a firm can charge for the talent without first accumulating the capital. The allocator's edge is supposed to be judgment—knowing which secondaries deals are mispriced, which continuation vehicles are worth the complexity, and which sellers need a buyer who can close rather than one who merely bids.

The two stories are two sides of the same market, with Golub spending capital to acquire talent and Gordian hoping to monetize talent without first raising a fund the size of Golub's. Both are responding to a market condition that is now impossible to miss: there is too much capital and too few invitations, and when capital is no longer the scarce input, the market reprices the people who know how to deploy it.

Golub's purchase was sourcing rather than a secondaries strategy. The strategies themselves are commodities—LP-led portfolios, GP-led continuation vehicles, tender offers, preferred equity—and what separates one buyer from another is whether they see the deal before it goes wide, underwrite it fast, and earn the seller's trust to close. Those qualities come down to people.

Gordian will be tested on precisely the deals other buyers walk away from, which is the right place to test an execution thesis. The obvious, widely marketed secondaries deals are won by capital; the complex ones are won by work, and a new firm without a nine-figure balance sheet has no choice but to go where the work is. The former allocator's bet is that the work is enough—that a seller with a hard deal will choose a buyer who understands it over a buyer who can simply pay more.

The risk in that bet is that execution without capital can become a fee business rather than an ownership business, but in secondaries fee income is not the point; you need to hold the assets you underwrite. Gordian's ability to raise capital from those who believe in its execution will determine whether the premise survives contact with a competitive process. Golub solved that problem in reverse: it brought the capital first and is now assembling the execution.

Neither move is small. A $1 billion commitment is large enough to move a secondaries market segment, and a senior hire from Northleaf is not a junior recruiting win. The former allocator's launch is smaller in disclosed capital but potentially larger in claim: that the next generation of secondaries firms will be built by investors who sat on the buy side, not by bankers who switched seats.

That claim is falsifiable. If the secondaries market continues to consolidate around the largest buyers, Gordian's execution-first model will be squeezed; if instead the flood of capital has made even large buyers lazy about complex deals, then a small, focused execution shop can win the deals the big platforms ignore. Golub appears to be preparing for the second outcome while funding itself like the first.

The sequence of Golub's commitment and Shafer's hire shows how the secondaries market now works: capital is no longer the thing you raise, it is the thing you use to buy the people who can raise, underwrite, and access deals. The $1 billion was the offer and the hire was the acceptance. Gordian is betting it can get the acceptance without the offer, and its ability to raise will show how the market prices that answer.

A $1 billion commitment before the team is an option on a strategy, not a strategy. Golub has not disclosed the structure, target return, or investment mandate; what it has disclosed is that it was willing to commit the money before the people, which is the strongest statement a firm can make about where it thinks the scarcity lies. If Golub thought the constraint were capital, it would not have started with capital; it started with capital because that was the only thing it could secure immediately, while the people required courtship.

The courtship produced Matt Shafer, and in a market where a single relationship can produce a decade of deal flow, Shafer's value is not in what he has already underwritten but in who returns his calls. That is the asset Golub bought with its $1 billion commitment; the capital was the signing bonus. Northleaf's loss is less about one person than about the map he carries. Secondaries is a small, referral-driven market, and a senior professional who has sat through GP-led processes, LP portfolio sales, and continuation vehicle negotiations becomes a node in that map. When he moves, the map moves with him, and Golub now holds a piece of that map, paid for in the only currency that clears immediately: committed capital.

Whatever Shafer's individual abilities—which are not assessable from outside—the move is a comment on market structure: in a market with too much capital and too few invitations, the invitation list is the asset, and Golub's pre-hire commitment was the price of admission to that list.

Gordian Investment Group is the other side of the same trade: a former Children's Health allocator has left to build a secondaries firm on the premise that execution, not capital, is the bottleneck, and that edge will be tested on the deals other buyers walk away from. It is a deliberate choice—walk toward the complexity that repels the capital-rich, and the capital-rich will never compete with you. The coverage identifies the founder only as a former Children's Health allocator, and that institutional background matters: allocators see every pitch, continuation vehicle, and GP-led secondaries process from the buyer's side, they know which deals are being shown to everyone and which to a short list, and they know why sellers choose certain buyers. That knowledge is the raw material of an execution-first secondaries firm.

Gordian has the knowledge; the open question is capital. A secondaries firm that cannot write a check is an advisor, and to be a principal it must raise. The premise that execution is the bottleneck will be tested by whether limited partners agree with that diagnosis: if they do, Gordian will raise fast; if they do not, the firm will discover that capital was never the scarce input for everyone, only for those who already had access. Golub avoided that test by bringing the capital first; Gordian is running it in real time. The difference between the two launches is one of sequencing: one firm bought the talent with money, the other is trying to buy money with talent, and in a market where both are scarce, the second trade is harder but the payoff to whoever proves it is larger.

Neither firm is a data point about the secondaries market's total size, and neither needs to be; the market's total size is no longer the question, the question is who gets to deploy it. Golub has answered that question for itself by hiring a relationship map, while Gordian is answering it by betting that a former allocator's judgment is a relationship map in its own right. This is the secondaries market's new shape: a barbell of capital-rich platforms buying talent and talent-rich startups trying to raise capital, with the middle—mediocre teams with no differentiated access and no capital advantage—being squeezed out. Golub and Gordian are not competing with each other today, but they are both defining the terms of competition for everyone else. The tell will be how quickly Gordian raises.